It is known, that the lesion of the upper digestive tract occupies a leading place among the chronic pathology of the digestive system. Their share is for 70–75% of the pathology of the gastrointestinal department. According to the Center of Medical Statistics of Ukraine, the incidence of gastric and duodenal ulcers has increased by 38.4% and the number of perforated ulcers among the adult population continues to increase on average by 5–8% for the past 10 years. It is well known today is the fact, that the origins of chronic diseases of the digestive tract in adults, which lead to disability, originate in childhood.
The proton pump inhibitors take the leading place among the recommended groups of drugs in the treatment of gastroduodenal lesion. Therefore, a marketing analysis of the oral proton pump inhibitors in doses optimally for use in pediatric practice was conducted. The assortment structure of investigational drugs by the country of origin and by the ATC-classification code were analyzed. About 60 trademarks of the oral proton pump inhibitors, which includes 6 INN and corresponds to A02AA ATC-classification code were registered in Ukraine as of February 2018, when the research was conducted. It was established, that the Ukrainian market of the oral proton pump inhibitors was formed predominantly by foreign producers, which accounts for 85% of the assortment. India was the leader among import countries. According to the obtained data, Ukrainian producers make up only 15% of the market. Six Ukrainian manufacturers mainly produce medicaments of omeprazole. It was found that the only representative of dexlansoprazole in the Ukrainian market was Dexylant.